Further studies of the role of hyperthermia in methamphetamine neurotoxicity.
The depletion of striatal dopamine (DA) that can occur after methamphetamine (METH) administration has been linked to METH-induced hyperthermia. The relationship between METH-induced hyperthermia, neurotoxicity (striatal DA depletions) and compounds that protect against METH neurotoxicity was further investigated in this study. Typically, rats exposed to METH die when their body temperatures exceed 41.3 degrees C but such hyperthermic rats can be saved by hypothermic intervention. Subsequently, rats saved by hypothermic intervention have greater depletion of striatal DA at an earlier time of onset (18 hr or less post-METH) than do METH-exposed rats that do not attain such high temperatures. Striatal damage was present 3 days post-METH in these hyperthermic rats, as assessed by silver degeneration of terminals and increases in the astrocytes that express glial fibrillary acidic protein immunoreactivity. By contrast, alterations in the number of [3H]dizoclipine (MK-801) binding sites in cortical or striatal membranes at 1, 3 or 14 days post-METH were not detected. The experiments showed that mean and maximal body temperature correlated well with striatal DA concentrations 3 days post-METH (r = -0.77, n = 58), which suggests a role for hyperthermia in METH neurotoxicity. However, hyperthermia (alone or with haloperidol present) induced by high ambient temperatures did not deplete striatal DA in the absence of METH. Haloperidol, diazepam and MK-801 all reduced METH-induced striatal DA depletion to a degree predicted by their inhibition of hyperthermia and increased ambient temperature abolished their neuroprotection. Although an interleukin-1 receptor antagonist reduced maximal body temperature enough to lower the lethality rate, it did not reduce the temperature sufficiently to block METH neurotoxicity. It was concluded that short- and long-term decreases in striatal DA levels depend on the degree of hyperthermia produced during METH exposure but cannot be produced by hyperthermia alone. In addition, several agents that block DA depletions do so by inhibiting METH-induced hyperthermia. Finally, the results suggested a role for interleukin-1 in the extreme hyperthermia and lethality produced by METH.
Bowyer
J F
JF
Division of Neurotoxicology, National Center for Toxicological Research, Jefferson, Arkansas.
Davies
D L
DL
Schmued
L
L
Broening
H W
HW
Newport
G D
GD
Slikker
W
W
Holson
R R
RR
D000818:Animals; D001665:Binding Sites; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D003975:Diazepam / Q000494:pharmacology; D016291:Dizocilpine Maleate / Q000378:metabolism; D004298:Dopamine / Q000172:deficiency; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D006220:Haloperidol / Q000494:pharmacology; D006979:Hyperthermia, Induced; D007036:Hypothermia, Induced; D007150:Immunohistochemistry; D007375:Interleukin-1 / Q000494:pharmacology; D008297:Male; D008694:Methamphetamine / Q000633:toxicity*; D009420:Nervous System / Q000187:drug effects*; D017397:Prefrontal Cortex / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D017470:Receptors, Glutamate / Q000378:metabolism
D005904:Glial Fibrillary Acidic Protein; D007375:Interleukin-1; D017470:Receptors, Glutamate; D008694:Methamphetamine; D016291:Dizocilpine Maleate; D006220:Haloperidol; D003975:Diazepam; D004298:Dopamine